Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BT5528 |
Synonyms | |
Therapy Description |
BT5528 is a bicyclic peptide targeting Epha2 in conjugation with a cytotoxin, which may specifically target Epha2-expressing tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 5854, PMID: 32398269). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BT5528 | BT-5528 | BT5528 is a bicyclic peptide targeting Epha2 in conjugation with a cytotoxin, which may specifically target Epha2-expressing tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 5854, PMID: 32398269). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04180371 | Phase Ib/II | BT5528 + Nivolumab BT5528 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Recruiting | USA | GBR | ESP | BEL | 1 |